Chartwell Molecular Company Profile
What is the competitive landscape for CHARTWELL MOLECULAR
CHARTWELL MOLECULAR has ninety approved drugs.
There are two tentative approvals on CHARTWELL MOLECULAR drugs.
Drugs and US Patents for Chartwell Molecular
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell Molecular | CARVEDILOL | carvedilol | TABLET;ORAL | 077474-001 | Sep 5, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chartwell Molecular | ACYCLOVIR | acyclovir | OINTMENT;TOPICAL | 206437-001 | Jul 31, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Chartwell Molecular | OLANZAPINE | olanzapine | TABLET, ORALLY DISINTEGRATING;ORAL | 203456-003 | Mar 16, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chartwell Molecular | LEVOFLOXACIN | levofloxacin | TABLET;ORAL | 076890-003 | Mar 30, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chartwell Molecular | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET;ORAL | 077388-001 | Jul 30, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Chartwell Molecular
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chartwell Molecular | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

